Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 50S ribosomal subunit, 23S rRNA peptide exit tunnel is a critical structural channel within the bacterial ribosome that extends from the peptidyl transferase center (PTC) to the exterior of the large subunit [1]. Its primary biological role is to provide a protected conduit for the nascent polypeptide chain as it is synthesized during translation, while also participating in translational regulation by sensing specific peptide sequences [2, 5]. The tunnel is approximately 80-100 Å long and is composed predominantly of 23S ribosomal RNA (rRNA) segments, which provide the chemical environment necessary for peptide transit [3]. In clinical medicine, this tunnel serves as a major pharmacological target for several important classes of antibiotics, including macrolides, lincosamides, and streptogramins [4]. These drugs bind to the upper part of the tunnel, physically blocking the exit of the growing protein chain and causing the ribosome to stall and eventually dissociate from the mRNA [5]. Resistance to these drugs is a significant global health challenge, often mediated by enzymes that methylate the 23S rRNA or by chromosomal mutations that alter the drug-binding pocket, thereby reducing antibiotic affinity [6]. [1] Wilson, D. N. (2014). Nature Reviews Microbiology. [2] Arenz, S., & Wilson, D. N. (2016). Cold Spring Harbor Perspectives in Medicine. [3] Dunkle, J. A., et al. (2010). PNAS. [4] Tenson, T., et al. (2003). Journal of Molecular Biology. [5] Vazquez-Laslop, N., & Mankin, A. S. (2018). Trends in Biochemical Sciences. [6] Roberts, M. C. (2008). FEMS Microbiology Letters.
Antibiotics bind to specific nucleotides (notably A2058 and A2059) within the 23S rRNA of the 50S subunit exit tunnel, sterically obstructing the passage of the nascent polypeptide chain. This blockage prevents peptide bond formation or triggers the premature release of peptidyl-tRNA, thereby inhibiting bacterial protein synthesis [1, 4, 5].
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 50S ribosomal subunit, 23S rRNA peptide exit tunnel (50S NPET).